[go: up one dir, main page]

AR108411A2 - HEPATITIS C VIRUS INHIBITORS - Google Patents

HEPATITIS C VIRUS INHIBITORS

Info

Publication number
AR108411A2
AR108411A2 ARP170101215A ARP170101215A AR108411A2 AR 108411 A2 AR108411 A2 AR 108411A2 AR P170101215 A ARP170101215 A AR P170101215A AR P170101215 A ARP170101215 A AR P170101215A AR 108411 A2 AR108411 A2 AR 108411A2
Authority
AR
Argentina
Prior art keywords
imidazol
pyrrolidinyl
biphenylyl
methyl
methyl carbamate
Prior art date
Application number
ARP170101215A
Other languages
Spanish (es)
Inventor
Lawrence G Hamann
Gan Wang
David R Langley
Fukang Yang
Laurent Denis R St
Lawrence B Snyder
Edward H Ruediger
Jeffrey Lee Romine
Van N Nguyen
Nicholas A Meanwell
Alain Martel
Omar D Lopez
Rico Lavoie
Clint A James
Jason Goodrich
Andrew C Good
Daniel H Deon
Makonen Belema
Carol Bachand
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of AR108411A2 publication Critical patent/AR108411A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto, caracterizado porque se selecciona de: ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; (1R,1’R)-2,2’-(4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil))bis(N,N-dimetil-2-oxo-1-feniletanamina); ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; ((1S)-1-(((2S)-2-(4-(4’-(2-((2S)-4,4-difluoro-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-4-il)-4-bifenilil)-1H-imidazol-2-il)-4,4-difluoro-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; ((1S)-1-(((1R,3R,5R)-3-(5-(4’-(2-((1R,3R,5R)-2-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-azabiciclo[3.1.0]hex-3-il)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-2-azabiciclo[3.1.0]hex-2-il)carbonil)-2-metilpropil)carbamato de metilo; ((1R)-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etil)carbamato de metilo; ((1S)-2-metil-1-(((2S)-2-(5-(4’-(2-((2S)-1-(N-2-pirimidinil-D-valil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)propil)carbamato de metilo; ((1R)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dimetilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-2-oxo-1-feniletil)carbamato de metilo; (4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil((1R)-2-oxo-1-fenil-2,1-etandiil)))biscarbamato de dimetilo; (1R)-N,N-dimetil-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etanamina; ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-(N-(metoxicarbonil)-L-alanil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; y ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3,3-dimetilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2,2-dimetilpropil)carbamato de metilo.Claim 1: A compound, characterized in that it is selected from: ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; (1R, 1'R) -2,2 '- (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl)) bis (N, N-dimethyl-2 -oxo-1-phenylethanamine); ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (diethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) methyl carbamate; ((1S) -1 - (((2S) -2- (4- (4 '- (2 - ((2S) -4,4-difluoro-1 - ((2S) -2 - ((methoxycarbonyl) amino ) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-4-yl) -4-biphenylyl) -1H-imidazol-2-yl) -4,4-difluoro-1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; ((1S) -1 - (((1R, 3R, 5R) -3- (5- (4 '- (2 - ((1R, 3R, 5R) -2 - ((2S) -2 - ((methoxycarbonyl ) amino) -3-methylbutanoyl) -2-azabicyclo [3.1.0] hex-3-yl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -2-azabicyclo [3.1.0] hex-2-yl) carbonyl) -2-methylpropyl) methyl carbamate; ((1R) -2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro-2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethyl) methyl carbamate; ((1S) -2-methyl-1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1- (N-2-pyrimidinyl-D-valil) -2- pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) propyl) methyl carbamate; ((1R) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (dimethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) Methyl -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -2-oxo-1-phenylethyl) methyl carbamate; (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl ((1R) -2-oxo-1-phenyl-2,1-ethanediyl))) dimethyl biscarbamate ; (1R) -N, N-dimethyl-2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro -2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethanamine; ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1- (N- (methoxycarbonyl) -L-alanyl) -2-pyrrolidinyl) -1H- methyl imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) carbamate; and ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3.3 -dimethylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2,2-dimethylpropyl) methyl carbamate.

ARP170101215A 2006-08-11 2017-05-09 HEPATITIS C VIRUS INHIBITORS AR108411A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83699606P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
AR108411A2 true AR108411A2 (en) 2018-08-15

Family

ID=41175598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101215A AR108411A2 (en) 2006-08-11 2017-05-09 HEPATITIS C VIRUS INHIBITORS

Country Status (3)

Country Link
CN (1) CN101558059B (en)
AR (1) AR108411A2 (en)
TW (1) TWI400072B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2550278A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
PT2730564T (en) * 2010-11-19 2018-07-24 Ligand Pharm Inc Heterocyclic Amines and Their Uses
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9212168B2 (en) * 2011-11-03 2015-12-15 Theravance Biopharma R&D Ip, Llc Hepatitis C virus inhibitors
CN103304551B (en) * 2012-03-14 2017-06-13 北京凯因科技股份有限公司 Hepatitis AG14361
JP6333372B2 (en) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Combination of hepatitis C virus inhibitors
CN105073740B (en) * 2014-01-21 2017-06-27 杭州普晒医药科技有限公司 Salt and crystalline form or amorphous form of a compound, preparation method thereof, pharmaceutical composition containing them and use
CN108084172A (en) * 2014-02-21 2018-05-29 常州寅盛药业有限公司 Anti- hepatitis C virus compound
WO2015184644A1 (en) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof
CN105524049B (en) * 2014-09-28 2018-11-06 正大天晴药业集团股份有限公司 Deuterated hepatitis C virus NS 5 A protein on NS inhibitor
CN104546780A (en) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 Daclatasvir film coating tablet preparation and preparation method thereof
WO2017076358A1 (en) * 2015-11-06 2017-05-11 苏州晶云药物科技有限公司 New crystal form of imidazolyl biphenyl compound salt and preparation method thereof
CN106496199A (en) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 His Wei of Dacca and its preparation method of intermediate
US10766912B2 (en) 2017-03-22 2020-09-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Silicon-containing compound for resistance to hepatitis C virus infection
CN115448892B (en) * 2022-09-19 2023-07-07 郑州铁路职业技术学院 A kind of synthetic method of benzothiadiazole heterocyclic compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005264A2 (en) * 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
TWI400072B (en) 2013-07-01
TW200934486A (en) 2009-08-16
CN101558059B (en) 2014-12-03
CN101558059A (en) 2009-10-14

Similar Documents

Publication Publication Date Title
AR108411A2 (en) HEPATITIS C VIRUS INHIBITORS
EA201000300A1 (en) METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C
MX2010001368A (en) Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2 s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)- 1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl )carbonyl)-2-methylpropyl)carbamate dihydrochloride sa
HRP20120440T1 (en) HEPATITIS VIRUS INHIBITORS C
NZ594981A (en) Hepatitis c virus inhibitors
PE20160800A1 (en) METHYL ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL COMBINATION )-1H-IMIDAZOL-5-IL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-IL-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE (DACLATASVIR) AND N-(TERT-BUTOXICARBONYL)-3- METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXYN-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOIL)-2-VINYLCYCLOPROPYL) -L-PROLINAMIDE (ASUNAPREVIR).
NZ595168A (en) Hepatitis c virus inhibitors
HRP20120706T1 (en) IMIDAZOLIL BIFENIL IMIDAZOLES AS INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) Solid compositions comprising an hcv inhibitor
NZ594068A (en) Substituted benzimidazole compounds as hepatitis c virus inhibitors
JP2013510857A5 (en)
PE20121354A1 (en) HEPATITIS C VIRUS INHIBITORS
JP2012518000A5 (en)
PE20140038A1 (en) ANTIVIRAL COMPOUNDS
JP2012522056A5 (en)
JP2010500415A5 (en)
EA200400183A1 (en) CRYSTALS CONTAINING SALT N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-Fluoro-2-OXO-1,2-DIHYDRO-3H-INDOL-3-ILIDEN) METHYL] -2,4-DIMETHYL- 1H-PIRROL-3-CARBOXAMIDE WITH APPLE ACID, METHODS FOR THEIR PRODUCTION AND THEIR COMPOSITION
PE20120533A1 (en) HEPATITIS C VIRUS INHIBITORS
JP2012522053A5 (en)
KR910006224A (en) Amino acid derivatives
JP2014513690A5 (en)
PE20061373A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE
ATE534375T1 (en) PHARMACEUTICAL COMPOSITION WITH N-Ä2- (DIETHYLAMINO)ETHYLÜ-5-Ä(5-FLUORO-1,2- DIHYDRO-2- OXO-3H-INDOL-3-YLIDEN)METHYLÜ-2,4-DIMETHYL-1H-PYRROLE- 3-CARBONIC ACID AMIDE
ZA201600006B (en) Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
AR065331A1 (en) DERIVATIVES OF BIFENILIL-1H-IMIDAZOL AND BIFENILDIIL-BIS (1H-IMIDAZOL-4,2) DIILO AS INHIBITORS OF THE VIRUS OF HEPATITIS C, COMPOSITIONS THAT UNDERSTAND AND THEIR USE IN THE TREATMENT OF AN INFECTION OF HCV.

Legal Events

Date Code Title Description
FB Suspension of granting procedure